INDIA – Dr. Reddy’s Laboratories has introduced its novel injectable product, Treprostinil Injection, for patients with pulmonary arterial hypertension (PAH) in the United States.

This injectable product will be used to reduce the risk of cardiovascular-related deaths and hospitalisations for patients with pulmonary hypertension in the US.

It is the therapeutic equivalent generic version of United Therapeutics Corporation’s Remodulin, which is approved by the U. S. Food and Drug Administration (USFDA).

Remodulin is a prescription medication used to treat adults with PAH, which is high blood pressure in the arteries of your lungs. Moreover, Remodulin can reduce symptoms associated with exercise.

Dr. Reddy’s Treprostinil Injection will be available in the form of vials in strengths of 20 mg/20 ml, 50 mg/20 ml, 100 mg/20 ml, and 200 mg/20 ml.

In the United States, the most common cause of pulmonary hypertension is left heart disease, such as left heart failure.

Dr. Reddy’s plans to roll out its generic injection to support the treatment of patients suffering from this rare, progressive disorder characterized by high blood pressure in the lungs’ arteries.

Similarly, Dr. Reddy’s has introduced its Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol, in the US market following the regulatory approval of the US FDA.

The generic drug is recommended for use in the treatment of inflammation, swelling, and pain associated with ocular surgery.

The Hyderabad-based drug major also launched Bortezomib for the treatment of multiple myeloma and mantle cell lymphoma in the US market.

The company also completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets.

Dr. Reddy’s is working closely with Fresenius Kabi, a European generic medicine manufacturer, to commercialise its proposed biosimilar of rituximab in the United States.

In March 2023, Dr. Reddy’s Laboratories sold certain non-core brands of the company in the dermatology segments to Eris Lifesciences Limited in a deal worth Rs. 275 crores (US$33.2 million).

The pharma giant took a deeper dive into healthcare in February by taking over the generic prescription product portfolio of Mayne Pharma in the United States for up to US$150 million.

Dr. Reddy’s also acquired the domestic sale rights for breast cancer drug PRIMCYV from Pfizer Products India Pvt Ltd.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.